File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3748/wjg.v23.i44.7863
- Scopus: eid_2-s2.0-85035241690
- PMID: 29209127
- WOS: WOS:000416214700006
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis
Title | Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis |
---|---|
Authors | |
Keywords | Aspartate aminotransferase Cirrhosis Hepatocellular carcinoma Platelet ratio index Primary biliary cholangitis Ursodeoxycholic acid |
Issue Date | 2017 |
Publisher | Baishideng Publishing Group. The Journal's web site is located at http://www.wjgnet.com/1007-9327/index.htm |
Citation | World Journal of Gastroenterology, 2017, v. 23 n. 44, p. 7863-7874 How to Cite? |
Abstract | AIM:
To investigate the usefulness of aspartate aminotransferase to platelet ratio index (APRI) in predicting hepatocellular carcinoma (HCC) risk in primary biliary cholangitis (PBC).
METHODS:
We identified PBC patients between 2000 and 2015 by searching the electronic medical database of a tertiary center. The hazard ratio (HR) of HCC with different risk factors was determined by Cox proportional hazards model.
RESULTS:
One hundred and forty-four PBC patients were recruited. Patients were diagnosed at a median age of 57.8 years [interquartile range (IQR): 48.7-71.5 years), and 41 (28.5%) patients had cirrhosis at baseline. The median follow-up duration was 6.9 years (range: 1.0-26.3 years). Twelve patients developed HCC, with an incidence rate of 10.6 cases per 1000 patient-years. The overall 5-, 10- and 15-year cumulative incidences of HCC were 2.3% 95%CI: 0%-4.8%), 8.4% (95%CI: 1.8%-14.5%) and 21.6% (6.8%-34.1%), respectively. Older age (HR = 1.07), cirrhosis (HR = 4.38) and APRI at 1 year after treatment (APRI-r1) > 0.54 (HR = 3.94) were independent factors for HCC development. APRI-r1, when combined with treatment response, further stratified HCC risk (log rank P < 0.05). The area under receiver operating curve of APRI-r1 in predicting HCC was 0.77 (95%CI: 0.64-0.88).
CONCLUSION:
APRI-r1 can be used to predict the development of HCC in PBC patients. Combination of APRI-r1 with treatment response can further stratify the HCC risk. |
Persistent Identifier | http://hdl.handle.net/10722/252246 |
ISSN | 2023 Impact Factor: 4.3 2023 SCImago Journal Rankings: 1.063 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cheung, KS | - |
dc.contributor.author | Seto, WKW | - |
dc.contributor.author | Fung, JYY | - |
dc.contributor.author | Mak, LY | - |
dc.contributor.author | Lai, CL | - |
dc.contributor.author | Yuen, RMF | - |
dc.date.accessioned | 2018-04-13T02:32:23Z | - |
dc.date.available | 2018-04-13T02:32:23Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | World Journal of Gastroenterology, 2017, v. 23 n. 44, p. 7863-7874 | - |
dc.identifier.issn | 1007-9327 | - |
dc.identifier.uri | http://hdl.handle.net/10722/252246 | - |
dc.description.abstract | AIM: To investigate the usefulness of aspartate aminotransferase to platelet ratio index (APRI) in predicting hepatocellular carcinoma (HCC) risk in primary biliary cholangitis (PBC). METHODS: We identified PBC patients between 2000 and 2015 by searching the electronic medical database of a tertiary center. The hazard ratio (HR) of HCC with different risk factors was determined by Cox proportional hazards model. RESULTS: One hundred and forty-four PBC patients were recruited. Patients were diagnosed at a median age of 57.8 years [interquartile range (IQR): 48.7-71.5 years), and 41 (28.5%) patients had cirrhosis at baseline. The median follow-up duration was 6.9 years (range: 1.0-26.3 years). Twelve patients developed HCC, with an incidence rate of 10.6 cases per 1000 patient-years. The overall 5-, 10- and 15-year cumulative incidences of HCC were 2.3% 95%CI: 0%-4.8%), 8.4% (95%CI: 1.8%-14.5%) and 21.6% (6.8%-34.1%), respectively. Older age (HR = 1.07), cirrhosis (HR = 4.38) and APRI at 1 year after treatment (APRI-r1) > 0.54 (HR = 3.94) were independent factors for HCC development. APRI-r1, when combined with treatment response, further stratified HCC risk (log rank P < 0.05). The area under receiver operating curve of APRI-r1 in predicting HCC was 0.77 (95%CI: 0.64-0.88). CONCLUSION: APRI-r1 can be used to predict the development of HCC in PBC patients. Combination of APRI-r1 with treatment response can further stratify the HCC risk. | - |
dc.language | eng | - |
dc.publisher | Baishideng Publishing Group. The Journal's web site is located at http://www.wjgnet.com/1007-9327/index.htm | - |
dc.relation.ispartof | World Journal of Gastroenterology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Aspartate aminotransferase | - |
dc.subject | Cirrhosis | - |
dc.subject | Hepatocellular carcinoma | - |
dc.subject | Platelet ratio index | - |
dc.subject | Primary biliary cholangitis | - |
dc.subject | Ursodeoxycholic acid | - |
dc.title | Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis | - |
dc.type | Article | - |
dc.identifier.email | Seto, WKW: wkseto@hku.hk | - |
dc.identifier.email | Fung, JYY: jfung@hkucc.hku.hk | - |
dc.identifier.email | Lai, CL: hrmelcl@hkucc.hku.hk | - |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | - |
dc.identifier.authority | Cheung, KS=rp02532 | - |
dc.identifier.authority | Seto, WKW=rp01659 | - |
dc.identifier.authority | Fung, JYY=rp00518 | - |
dc.identifier.authority | Lai, CL=rp00314 | - |
dc.identifier.authority | Yuen, RMF=rp00479 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3748/wjg.v23.i44.7863 | - |
dc.identifier.pmid | 29209127 | - |
dc.identifier.pmcid | PMC5703915 | - |
dc.identifier.scopus | eid_2-s2.0-85035241690 | - |
dc.identifier.hkuros | 284779 | - |
dc.identifier.volume | 23 | - |
dc.identifier.issue | 44 | - |
dc.identifier.spage | 7863 | - |
dc.identifier.epage | 7874 | - |
dc.identifier.isi | WOS:000416214700006 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 1007-9327 | - |